Status:

COMPLETED

Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy

Lead Sponsor:

Chronic Liver Disease Foundation

Collaborating Sponsors:

SCRI Development Innovations, LLC

Merck Sharp & Dohme LLC

Conditions:

Chronic Hepatitis C

Genotype 1

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

The purpose of this study is to evaluate the impact of a physician directed education program on treatment compliance of hepatitis C patients administered triple drug therapy of pegylated interferon, ...

Detailed Description

The new treatment paradigm for HCV in the era of protease inhibitors will add a level of complexity that was previously not seen with pegylated interferon and ribavirin. In addition to new concepts su...

Eligibility Criteria

Inclusion

  • Chronic Hepatitis C (HCV) genotype 1
  • Detectable HCV-RNA within 180 days of screening
  • Age ≥ 18 years
  • Weight \> 40 kg
  • Patient and partner(s) must agree to use acceptable methods of contraception
  • Written informed consent

Exclusion

  • Known co-infection with HIV or HBV
  • Previous interferon or ribavirin regimen requiring discontinuation for an adverse event considered related to ribavirin and/or interferon
  • Currently taking or planning on taking any prohibited medications
  • Evidence of decompensated liver disease including the presence of clinical ascites, bleeding varices, or hepatic encephalopathy
  • Diabetes and/or hypertension with clinically significant ocular examination findings
  • Pre-existing psychiatric condition(s)
  • History of severe and uncontrolled psychiatric disorders
  • Active alcohol or drug abuse (not including marijuana)
  • Pre-existing medical condition that could interfere with the patient's participation in the study
  • Chronic obstructive pulmonary disease
  • Abnormal lab values

Key Trial Info

Start Date :

December 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2014

Estimated Enrollment :

197 Patients enrolled

Trial Details

Trial ID

NCT01405027

Start Date

December 1 2011

End Date

July 1 2014

Last Update

January 6 2015

Active Locations (43)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 11 (43 locations)

1

California Liver Institute

Beverly Hills, California, United States, 90210

2

Samuel Burstein, MD

Calabasas, California, United States, 91302

3

William Katkov, MD

Santa Monica, California, United States, 90404

4

Sutha Sachar, MD

Torrance, California, United States, 90277